

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
 Approved for use through 10/31/99. OMB 0654-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/052,005
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles, L., Jr.
		Attorney Docket Number	MPI98-031CP1DV1CPACN1M
Sheet	1	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
CP	A3 ✓	Amason, T. and Ellison, M.J., "Stress resistance in <i>Saccharomyces cerevisiae</i> is strongly correlated with assembly of a novel type of multiubiquitin chain", <i>Molecular and Cell Biology</i> , Volume 14, Number 12, pages 7876-7883 (1994)	
	A5 ✓	Auphan, N., et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis" <i>Science</i> , Volume 270, pages 286-290 (1995)	
	A6 ✓	Baeuerle, P. and Henkel, T., "Function and Activation of NF-κB in the Immune System", <i>Annual Review of Immunology</i> , Volume 12, pages 141-179 (1994)	
	A11 ✓	Blank, J., et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3", <i>The Journal of Biological Chemistry</i> , Volume 271, Number 10, pages 5361-5368 (1996)	
	B1 ✓	Chen, P., et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MATα2 Repressor", <i>Cell</i> , Volume 74, pages 357-369 (1993)	
	B4 ✓	Chen, Z., et al., "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multiubiquitin Chain Synthesis via Lysine 48 of Ubiquitin", <i>The Journal of Biological Chemistry</i> , Volume 265, Number 35, pages 21835-21842 (1990)	
	B5 ✓	Choi, K., et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in <i>S. cerevisiae</i> ", <i>Cell</i> , Volume 78, pages 499-512 (1994)	
	B7 ✓	Derijard, B., et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Volume 267, pages 682-685 (1995)	
	B8 ✓	Derijard, B., et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-RAS That Binds and Phosphorylates the c-Jun Activation Domain", <i>Cell</i> , Volume 76, pages 1025-1037 (1994)	
	B11 ✓	DiDonato, J., et al., "Phosphorylation of IκBα Precedes but is Not Sufficient for its Dissociation from NF-κB", <i>Molecular and Cellular Biology</i> , Volume 15, Number 3, pages 1302-1311 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (10-86)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/052005
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
Sheet 2 of 5	Attorney Docket Number	MPI98-031CP1DV1CPACN1M	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
CA	B13	Finco, T., et al., "Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors", Proceedings of the National Academy of Sciences USA, Volume 91, pages 11884-11888 (1994)	
	B15	Finco, T., et al., "Mechanistic Aspects of NF-κB Regulation: The Emerging Role of Phosphorylation and Proteolysis", Immunity, Volume 3, pages 263-272 (1995)	
	B16	Francis, S. and Corbin, D., "Structure and Function of Cyclic Nucleotide-Dependent Protein Kinases", Annual Review of Physiology, Volume 56, pages 237-272 (1994)	
	B18	Goldberg, A., "Functions of the Proteasome: The Lysis at the End of the Tunnel", Science, Volume 268, pages 522-523 (1995)	
	C1	Gupta, S., et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway", Science, Volume 267, pages 389-393 (1995)	
	C2	Haskill, S., et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes IκB-like Activity", Cell, Volume 65, pages 1281-1289 (1991)	
	C4	Hershko, A. and Heller, H., "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates", Biochemical and Biophysical Research Communications, Volume 128, Number 3, pages 1079-1086 (1985)	
	C6	Hibi, M., et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", Genes and Development, Volume 7, pages 2135-2148 (1993)	
CA	C7	Higgins, K., et al., "Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression", Proceedings of the National Academy of Sciences USA, Volume 90, pages 9901-9905 (1993)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/052005
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
		Attorney Docket Number	MPI98-031CP1DV1CPACN1M
Sheet	3	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C8	Hirano, M., et al., "MEK Kinase is Involved in Tumor Necrosis Factor α -Induced NF- κ B Activation and Degradation of I κ B- α ", The Journal of Biological Chemistry, Volume 273 277 , Number 22, pages 13234-13238 (1996)	
	C11	Lange-Carter, C.A., et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf", Science, Volume 260, pages 315-319 (1993)	
	C13	Lin, Y.-C., et al., "Activation of NF- κ B requires proteolysis of the inhibitor I κ B- α : Signal-induced phosphorylation of I κ B- α alone does not release active NF- κ B", Proceedings of the National Academy of Sciences USA, Volume 92, pages 552-556 (1995)	
	C15	Mellits, K.H., et al., "Proteolytic degradation of MAD3 (I κ B α) and enhanced processing of the NF- κ B precursor p105 are obligatory steps in the activation of NF- κ B", Nucleic Acids Research, Volume 21, Number 22, pages 5059-5066 (1993)	
	C16	Miyamoto, S., et al., "Tumor necrosis factor α -induced phosphorylation of I κ B α is a signal for its degradation but not dissociation from NF- κ B", Proceedings of the National Academy of Sciences USA, Volume 91, pages 12740-12744 (1994)	
	D5	Read, M.A., et al., "The Proteasome Pathway is Required for Cytokine-Induced Endothelial-Leukocyte Adhesion Molecule Expression", Immunity, Volume 2, pages 493-506 (1995)	
	D10	Siebenlist, U., et al., "Structure, Regulation and Function of NF- κ B", Annual Review of Cell Biology, Volume 10, pages 405-455 (1994)	
	D12	Thanos, D. and Maniatis, T., "NF- κ B: A Lesson in Family Values", Cell, Volume 80, pages 529-532 (1995)	
	D13	Thevenin, C., et al., "Induction of Nuclear Factor- κ B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, a Specific Inhibitor of Phosphatases 1 and 2A", New Biologist, Volume 2, Number 9, pages 793-800 (1990)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/06B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/052005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
		Attorney Docket Number	MPI98-031CP1DV1CPACN1M
Sheet	4	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
CN	D15	Traenckner, E.B., et al., "Phosphorylation of Human I κ B- α on Serines 32 and 36 Controls I κ B- α Proteolysis and NF- κ B Activation in Response to Diverse Stimuli", The EMBO Journal, Volume 14, Number 12, pages 2876-2883 (1995)	
	E3	Yang, Y.-L., et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase", The EMBO Journal, Volume 14, Number 24, pages 6095-6106 (1995)	
CN	F1	Xu, S., et al., "Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain", Proceedings of the National Academy of Sciences USA, Volume 93, pages 5291-5295 (1996)	
	F2	Khoshnan, A., et al., "The Physical Association of Protein Kinase C θ with a Lipid Raft-Associated Inhibitor of κ B Factor Kinase (IKK) Complex Plays a Role in the Activation of the NF- κ B Cascade by TCR and CD28 ^{1m} ", The Journal of Immunology, Volume 165, pages 6933-6940 (2000)	
	F3	DiDonato, J.A., et al., "A Cytokine-responsive I κ B kinase that Activates the Transcription Factor NF- κ B", Nature, Volume 388, pages 548-554 (August 1997)	
	F4	Miller, B.S. and Zandi, E., "Complete Reconstitution of Human I κ B Kinase (IKK) Complex in Yeast", The Journal of Biological Chemistry, Volume 276, Number 39, pages 36320-36326 (September 28, 2001)	
	F5	Fu, D.-X., et al., "Human T-lymphotropic Virus Type I Tax Activates I- κ B Kinase by Inhibiting I- κ B Kinase-associated Serine/Threonine Protein Phosphatase 2A", The Journal of Biological Chemistry, Volume 278, Number 3, pages 1487-1493 (January 17, 2003)	
	F6	Storz, P. and Toker, A., "Protein kinase D mediates a stress-induced NF- κ B Activation and Survival Pathway", The EMBO Journal, Volume 22, Number 1, pages 109-120 (2003)	
CN	F7	Yang, J., et al., "The Essential Role of MEKK3 in TNF-induced NF- κ B Activation", Nature Immunology, Volume 2, Number 7, pages 620-624 (July 2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

+


PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicati n Number	10/052005
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
Sheet	5	of	5
		Attorney Docket Number	MPI96-031CP1DV1CPACN1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ	F8 ✓	Zhao, Q. and Lee, F.S., "Mitogen-activated Protein Kinase/ERK Kinase Kinases 2 and 3 Activate Nuclear Factor-kB through IκB Kinase-α and IκB Kinase-β", The Journal of Biological Chemistry, Volume 274, Number 13, pages 8355-8358 (March 26, 1999)	
	F9 ✓	Tojima, Y., et al., "NAK is an IκB kinase-activating kinase", Nature, Volume 404, pages 778-782 (April 13, 2000)	
	F10 ✓	Wang, C., et al., "TAK1 is a Ubiquitin-dependent kinase of MKK and IKK", Nature, Volume 412, pages 346-351 (July 19, 2001)	
	F11 ✓	Regnier, C.H., et al., "Identification and Characterization of an IκB Kinase", Cell, Volume 90, pages 373-383 (July 25, 1997)	
CJ	F12 ✓	Connelly, M.A. and Marcu, K.B., "CHUK, A New Member of the Helix-loop-helix and Leucine Zipper Families of Interacting Proteins, Contains a Serine-Threonine Kinase Catalytic Domain", Cellular and Molecular Biology Research, Volume 41, Number 6, pages 537-549 (1995)	

Examiner Signature		Date Considered	9/17/03
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.